Figure Legends:
Figure 1: graphical representation of the cohorts for analysis
Figure 2: Overall survival stratified for busulfan pharmacokinetic targeting. The targeted group 3-year OS of 79.9% (95% CI 69.4% - 90.4%) compared with the untargeted group: 75.0% (95% CI 62.5% - 87.5%). P value = 0.6
Figure 3: Event Free survival stratified for busulfan pharmacokinetic targeting. The targeted group 2-year EFS of 79.9% (95% CI 69.4% - 90.4%) compared with the untargeted group: 66.7% (95% CI 53.1% - 80.3%). P value = 0.4
Figure 4: Cumulative incidence of relapse (CIR). 3 events, with CIR = 11.3% (95% CI 5.1% - 17.5%)
Figure 5: Non-Relapse mortality stratified for busulfan pharmacokinetic levels. The targeted group NRM of 15.4% (95% CI 5.4% - 25.4%) compared with the untargeted group: 16.7% (95% CI 5.9% - 27.5%). P value = 0.7